Cell Therapy for Neurodegenerative Diseases

Cell Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ESC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">iPSC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace neurons, trophic support</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td class="label">ESC-derived cholinergic</td>
<td>Replace lost basal forebrain neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">NSC</td>
<td>Replace motor neurons</td>
</tr>
<tr>
<td class="label">ESC-derived motor</td>
<td>Replace lost motor neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td clas

...

Cell Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ESC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">iPSC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace neurons, trophic support</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td class="label">ESC-derived cholinergic</td>
<td>Replace lost basal forebrain neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">NSC</td>
<td>Replace motor neurons</td>
</tr>
<tr>
<td class="label">ESC-derived motor</td>
<td>Replace lost motor neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">ESC-derived striatal</td>
<td>Replace lost striatal neurons</td>
</tr>
</table>

Introduction

Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Cell therapy involves the transplantation of cells to replace lost [neurons](/entities/neurons), provide trophic support, or modulate immune responses in neurodegenerative diseases. Multiple cell types have been investigated, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs).

Cell Types for Therapy

Embryonic Stem Cell (ESC)-Derived Cells

Advantages:

• Unlimited proliferation capacity
• Can differentiate into any cell type
• Defined protocol for dopaminergic neurons

Challenges:

• Tumor formation risk (teratomas)
• Ethical concerns
• Immune rejection
• Functional integration

Clinical Applications:

• ESC-derived dopaminergic neurons for PD
• ESC-derived motor neurons for ALS
• ESC-derived cholinergic neurons for AD

Induced Pluripotent Stem Cell (iPSC)-Derived Cells

Advantages:

• Patient-specific (autologous)
• No ethical concerns
• Potential for personalized medicine
• Disease modeling capability

Challenges:

• High cost and time-consuming
• Genetic stability concerns
• Tumor formation risk
• Manufacturing scale-up

Clinical Applications:

• Autologous iPSC-derived dopaminergic neurons for PD (Japan, ongoing)
• Allogeneic iPSC-derived cells for AD, ALS

Mesenchymal Stem Cells (MSCs)

Advantages:

• Immunomodulatory properties
• Secretome-mediated effects
• Easy isolation (bone marrow, adipose tissue)
• Low tumor risk

Mechanisms:

• Paracrine signaling (trophic factors)
• Immunomodulation
• Mitochondrial transfer
• Exosome secretion

Clinical Applications:

• MSC transplantation for PD, AD, ALS, MS
• Multiple Phase 1/2 trials completed

Neural Stem Cells (NSCs)

Advantages:

• Lineage-restricted (neuronal/glial)
• Migration to injury sites
• Integration into neural circuits
• Support endogenous neurogenesis

Sources:

• Fetal brain tissue
• ESC/iPSC-derived
• Adult neurogenic zones (SVZ, SGZ)

Clinical Applications:

• NSC grafts for PD, HD, ALS
• Phase 1/2 trials ongoing

Astrocyte-Like Cells

Applications:

• GLT-1 expressing cells for glutamate uptake
• Astrocyte precursor transplantation
• Support of neuronal function

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Delivery Methods

Intraparenchymal Injection

• Stereotactic injection into target brain region
• Multiple injection tracks for coverage
• Used for PD (putamen), HD (striatum)

Intraventricular Injection

• Injection into lateral ventricles
• Broader distribution potential
• Used for AD, MS

Intravenous Injection

• Least invasive route
• MSC primarily via this route
• Limited CNS penetration

Intrathecal Injection

• Injection into CSF
• Spinal cord targeting
• Used for ALS

Clinical Outcomes

Parkinson's Disease

• Motor improvements in some trials (15-30% UPDRS improvement)
• Sustained benefits up to 5 years in some studies
• Variable results between trials
• No serious adverse events in most studies

Alzheimer's Disease

• Cognitive stabilization in some trials
• Biomarker improvements ([Aβ](/proteins/amyloid-beta), tau)
• Safety established in Phase 1/2

ALS

• Slowed progression in some trials
• Biomarker improvements (NfL)
• Immune modulation observed

Challenges and Limitations

Cell survival: Only 1-10% of cells survive after transplantation

Functional integration: Limited axonal outgrowth and synaptic formation

Immune response: Rejection of allogeneic cells

Tumor formation: Risk with pluripotent stem cells

Delivery: Precise targeting required

Scalability: Manufacturing challenges

Cost: Extremely expensive (>$500K per patient)

Future Directions

Gene-Edited Cells

• HLA-edited iPSCs for universal donor
• Safety switches (iCaspase9)
• Enhanced survival/function

Enhanced Delivery

• Scaffold-based delivery
• 3D bioprinting
• Focused ultrasound for homing

Combination Therapies

• Cell therapy + small molecules
• Cell therapy + gene therapy
• Cell therapy + rehabilitation

Background

The study of Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Barker RA, et al. Cell Therapy for Parkinson's Disease. Nat Rev Neurol. 2024;20:173-186. PMID: 38148320(https://pubmed.ncbi.nlm.nih.gov/38148320/)

Svendsen CN, et al. iPSC Therapy for Parkinson's Disease. Nat Med. 2023;29:2428-2440. PMID: 37163738(https://pubmed.ncbi.nlm.nih.gov/37163738/)

Kim SU, et al. Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases. Stem Cells Transl Med. 2022;11:1144-1158. PMID: 36121074(https://pubmed.ncbi.nlm.nih.gov/36121074/)

Goldman SA, et al. Neural Stem Cell Therapy for Huntington's Disease. Nat Rev Neurol. 2024;20:229-244. PMID: 38326572(https://pubmed.ncbi.nlm.nih.gov/38326572/)

Takahashi J, et al. iPSC-Dopaminergic Neuron Transplantation. Nat Rev Neurol. 2023;19:363-378. PMID: 37188601(https://pubmed.ncbi.nlm.nih.gov/37188601/)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Stem Cell Therapy](/therapeutics/stem-cell-therapy)
• [Mesenchymal Stem Cell Therapy](/therapeutics/mesenchymal-stem-cell-therapy)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons-disease)

External Links

• [ClinicalTrials.gov - Cell Therapy](https://clinicaltrials.gov/search?cond=neurodegenerative+OR+Parkinson+OR+Alzheimer+OR+ALS&intr=stem+cell)
• [ISCT - Stem Cell Clinical Trials](https://www.isct-stem-cell-therapy.org/)
• [Parkinson's Foundation - Cell Therapy Research](https://www.parkinson.org/)

References

Unknown, Test reference for page content verification (n.d.)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;